M&T Bank Corp Sells 1,108 Shares of Sanofi (NASDAQ:SNY)

M&T Bank Corp lowered its stake in shares of Sanofi (NASDAQ:SNY) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,556 shares of the company’s stock after selling 1,108 shares during the quarter. M&T Bank Corp’s holdings in Sanofi were worth $2,364,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Rise Advisors LLC grew its holdings in shares of Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares in the last quarter. Salem Investment Counselors Inc. bought a new position in Sanofi in the 4th quarter valued at about $27,000. Venturi Wealth Management LLC raised its position in shares of Sanofi by 163.5% in the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after buying an additional 332 shares in the last quarter. McIlrath & Eck LLC lifted its holdings in shares of Sanofi by 143.3% during the 4th quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock worth $30,000 after acquiring an additional 361 shares during the period. Finally, Farmers & Merchants Trust Co of Chambersburg PA boosted its position in shares of Sanofi by 115.6% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock worth $37,000 after acquiring an additional 400 shares in the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Up 1.1 %

Shares of NASDAQ:SNY opened at $50.10 on Thursday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.72. The company has a market capitalization of $126.73 billion, a PE ratio of 25.18, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61. The company has a fifty day moving average of $47.95 and a 200-day moving average of $48.12.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a dividend of $1.478 per share. This represents a dividend yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio (DPR) is presently 69.35%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SNY. TheStreet cut Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. Morgan Stanley initiated coverage on Sanofi in a research note on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective on the stock. Finally, StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.